Ofichem unifies brands under single CDMO and pharmaceutical supplier

Ofichem unifies brands under single CDMO and pharmaceutical supplier

One Ofichem. One voice. A more connected approach to pharmaceutical partnerships.

[Ter Apel, Netherlands] - April 8, 2026  - Ofichem has brought its brands - Ofichem BV, Ofipharma, Ofimedicine, Labatorium Ofichem, Ofichem Uppsala, and Avivia - together as one family-owned CDMO and pharmaceutical supplier, marking a strategic step in its evolution.

From April 1, all business units will operate under the Ofichem trading name. The move brings together Ofichem’s capabilities across drug substance, drug product, and sourcing and distribution into one integrated offering. 

As Ofichem has grown, its capabilities have been delivered across multiple brands, while at the same time, pharmaceutical and biotech companies are increasingly looking to reduce complexity by working with fewer, more integrated partners that can support them across the lifecycle of their drug.

Bringing everything together as one Ofichem gives customers a more connected view of the organisation and simplifies how they engage, while maintaining the same quality, compliance and responsiveness they rely on.

“Over time, we’ve built a business with real depth across API, drug substance, drug product and supply,” said Weite Oldenziel, CEO of Ofichem. “What has been less visible is how those capabilities come together. Combining all brands under the Ofichem umbrella makes that clear as we continue to support our customers in a more connected and consistent way.”

By aligning its teams, capabilities and communications, Ofichem is making it easier for customers to access the full value of the organisation, from early-stage support to commercial supply.

“This is not a change to what we do, but to how clearly we present it,” added Oldenziel. “Our customers can expect the same reliability and flexibility, now with greater visibility of our comprehensive support as we strive to give every medicine the best chance of fulfilling its potential.” 

The move also strengthens Ofichem’s position as a European-based CDMO partner, offering regulatory expertise, supply chain reliability, and closer collaboration in a market increasingly focused on security, transparency and control.

-ENDS-

Note:

The transition reflects a unified commercial identity, with no changes to legal entities. There is no impact on existing contracts, services, quality systems or points of contact, and customers will continue to work with the same teams.

About Ofichem

Ofichem is a family-owned CDMO and pharmaceutical supplier trusted by pharma and compounding customers with responsive, reliable solutions across API, drug substances and drug products. With over 50 years of regulatory expertise and GMP-certified operations, Ofichem delivers flexible, audit-ready services tailored to client needs, from small batches to larger-scale supply. Known for clarity, speed, and a no-nonsense approach, the company combines technical excellence with a partnership mindset. Ofichem brings the experience to guide and the commitment to stand by its clients, building strong relationships that last. Its mission is to guide pharmaceutical companies with clarity, confidence, and heart.